



PRESS RELEASE
For immediate release

PERCEPTRONIX ANNOUNCES THE OPENING OF ITS FIRST CLINICAL QUANTITATIVE CYTOLOGY LAB

VANCOUVER, CANADA (March 30, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announced today the opening of its first Quantitative Cytology Laboratory in Vancouver, British Columbia.

Perceptronix Quantitative Cytology Laboratory offers advanced quantitative clinical laboratory services to assist clinicians in the diagnosis and prognosis of cancer. The lab utilizes the Perceptronix ClearCyte™ Quantitative Cytology System and Clear2C™ Quantitative DNA Staining Kit to measure gross genomic aberrations (DNA ploidy – see below) in tissue samples. Both devices received Health Canada Class II medical device approval earlier this year.

ClearCyte™ is an automated microscopy imaging system used to measure DNA properties in cell samples of different tissues such as breast, bladder, mouth, lung etc. Combined with expert interactive review of cells, ClearCyte™ test results may provide clinicians with valuable information related to the clinical diagnosis and prognosis of cancer.

Dr. Jasenka Maticic, FRCPC, has been appointed as Medical Director of the Perceptronix Quantitative Cytology Laboratory. Dr. Maticic is a general pathologist with many years of experience in both gynecological and non-gynecological cytology.

“Dr. Maticic is a key addition to our team and we are very fortunate to have access to her extensive expertise as we begin to offer our laboratory services and technologies to clinicians worldwide,” stated Milton Wong, Perceptronix CEO.

Notes to Editors

“Quantitative Cytology” is the precise measurement of cell features. This technique permits the detection of very extensive changes to the DNA of cells (also called DNA ploidy or Gross Genomic Aberrations), which often are signatures of cancer cells. The ClearCyte™ technology combines fully automated imaging and measurement of cells on a microscope slide with the ability to interactively review any or all of the cells in the context of their measurements for accurate specimen assessment. When added to other clinical information, these cell measurements may provide physicians with important diagnostic and prognostic information about the patient.

About Perceptronix Medical Inc. (www.perceptronix.com)

Perceptronix (www.perceptronix.com) is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with the BC Cancer Agency (www.bccancer.bc.ca), a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs.



Perceptronix's goal is to develop and commercialize a suite of technologies to approach cancer diagnosis comprehensively: early detection, localization, diagnosis and follow-up. The first of Perceptronix's technologies to receive regulatory approval is the ClearCyte™ Quantitative Cytology System and its associated Clear2C™ Quantitative DNA Staining Kit which assist physicians with clinical diagnosis and prognosis of cancer. The Perceptronix product pipeline also includes ClearSign™, a sputum based early lung cancer detection test, ClearVu™ and ClearVu™ Elite, simultaneous and spectral fluorescence/white light endoscopy systems, and ClearPath™, an aid to the definitive diagnosis of biopsy sections.

Contact:

Susan Grose, Corporate Secretary
Perceptronix Medical Inc.
Ste. 400, 555 West 8th Avenue
Vancouver, Canada V5Z 1C6
Phone: (604) 707 – 9037
info@perceptronix.com